|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/06/21 AbbVie Inc. 8-K:5 12/31/20 11:310K Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 52K 7: R1 Cover HTML 75K 9: XML IDEA XML File -- Filing Summary XML 12K 6: XML XBRL Instance -- tm211488d1_8k_htm XML 44K 8: EXCEL IDEA Workbook of Financial Reports XLSX 6K 3: EX-101.DEF XBRL Definitions -- abbv-20201231_def XML 87K 4: EX-101.LAB XBRL Labels -- abbv-20201231_lab XML 129K 5: EX-101.PRE XBRL Presentations -- abbv-20201231_pre XML 82K 2: EX-101.SCH XBRL Schema -- abbv-20201231 XSD 19K 10: JSON XBRL Instance as JSON Data -- MetaLinks 30± 39K 11: ZIP XBRL Zipped Folder -- 0001104659-21-001570-xbrl Zip 17K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): i December 31, 2020
(Exact Name of Registrant as Specified in its Charter)
_______________________________________________
| i Delaware | i 001-35565 | i 32-0375147 | ||
| (State or other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
_______________________________________________
i North Chicago, i Illinois i 60064-6400
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: ( i 847) i 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| i ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| i ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| i ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| i ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
C:
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
(e) The agreements regarding change in control by and between AbbVie and its named executive officers have been renewed through December 31, 2022 in accordance with the agreement terms. There were no other changes to the agreements. The form of change in control agreement was filed as Exhibit 10.13 of Amendment No. 5 to the Company’s Registration Statement on Form 10 filed on November 16, 2012.
C:
C: 2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ABBVIE INC. | ||
| Date: January 6, 2021 | By: | /s/ Timothy J. Richmond |
| Name: | Timothy J. Richmond | |
| Title: | Executive Vice President, Chief Human Resources Officer | |
C:
3
C:
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 12/31/22 | ||||
| Filed on: | 1/6/21 | |||
| For Period end: | 12/31/20 | 10-K, 11-K, 4, SD | ||
| 11/16/12 | 10-12B/A, CORRESP | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/12/21 AbbVie Inc. S-8 5/12/21 3:104K Toppan Merrill/FA |